Medigen Vaccine (Taiwan) Performance
| 6547 Stock | TWD 38.50 0.20 0.52% |
The company secures a Beta (Market Risk) of 0.23, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Medigen Vaccine's returns are expected to increase less than the market. However, during the bear market, the loss of holding Medigen Vaccine is expected to be smaller as well. At this point, Medigen Vaccine Biologics has a negative expected return of -0.35%. Please make sure to verify Medigen Vaccine's market risk adjusted performance, coefficient of variation, information ratio, as well as the relationship between the mean deviation and standard deviation , to decide if Medigen Vaccine Biologics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Medigen Vaccine Biologics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in December 2024. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors. ...more
| Begin Period Cash Flow | 1.7 B | |
| Total Cashflows From Investing Activities | -930.7 M |
Medigen |
Medigen Vaccine Relative Risk vs. Return Landscape
If you would invest 4,830 in Medigen Vaccine Biologics on August 28, 2024 and sell it today you would lose (980.00) from holding Medigen Vaccine Biologics or give up 20.29% of portfolio value over 90 days. Medigen Vaccine Biologics is generating negative expected returns and assumes 1.4868% volatility on return distribution over the 90 days horizon. Simply put, 13% of stocks are less volatile than Medigen, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Medigen Vaccine Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medigen Vaccine's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Medigen Vaccine Biologics, and traders can use it to determine the average amount a Medigen Vaccine's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2382
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 6547 |
Estimated Market Risk
| 1.49 actual daily | 13 87% of assets are more volatile |
Expected Return
| -0.35 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.24 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Medigen Vaccine is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Medigen Vaccine by adding Medigen Vaccine to a well-diversified portfolio.
Medigen Vaccine Fundamentals Growth
Medigen Stock prices reflect investors' perceptions of the future prospects and financial health of Medigen Vaccine, and Medigen Vaccine fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medigen Stock performance.
| Return On Equity | 0.0662 | |||
| Return On Asset | 0.0209 | |||
| Profit Margin | 0.13 % | |||
| Operating Margin | 0.09 % | |||
| Current Valuation | 24.78 B | |||
| Shares Outstanding | 327.2 M | |||
| Price To Earning | 34.63 X | |||
| Price To Book | 4.71 X | |||
| Price To Sales | 10.51 X | |||
| Revenue | 3.28 B | |||
| EBITDA | 1.53 B | |||
| Cash And Equivalents | 2.12 B | |||
| Cash Per Share | 9.95 X | |||
| Total Debt | 286.54 M | |||
| Debt To Equity | 0.06 % | |||
| Book Value Per Share | 17.52 X | |||
| Cash Flow From Operations | 579.89 M | |||
| Earnings Per Share | 0.91 X | |||
| Total Asset | 5.3 B | |||
About Medigen Vaccine Performance
Evaluating Medigen Vaccine's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Medigen Vaccine has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Medigen Vaccine has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp. MEDIGEN VACCINE operates under Biotechnology classification in Taiwan and is traded on Taiwan OTC Exchange.Things to note about Medigen Vaccine Biologics performance evaluation
Checking the ongoing alerts about Medigen Vaccine for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Medigen Vaccine Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Medigen Vaccine generated a negative expected return over the last 90 days | |
| About 28.0% of the company shares are owned by insiders or employees |
- Analyzing Medigen Vaccine's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medigen Vaccine's stock is overvalued or undervalued compared to its peers.
- Examining Medigen Vaccine's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Medigen Vaccine's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medigen Vaccine's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Medigen Vaccine's stock. These opinions can provide insight into Medigen Vaccine's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Medigen Stock Analysis
When running Medigen Vaccine's price analysis, check to measure Medigen Vaccine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medigen Vaccine is operating at the current time. Most of Medigen Vaccine's value examination focuses on studying past and present price action to predict the probability of Medigen Vaccine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medigen Vaccine's price. Additionally, you may evaluate how the addition of Medigen Vaccine to your portfolios can decrease your overall portfolio volatility.